Apar Kishor Ganti on Muck Rack

Apar Kishor Ganti

Omaha
As seen in: JCO Oncology Practice, PLOS, Taylor & Francis Online, JAMA Oncology, Dove Medical Press, MDEdge, Chinese Clinical Oncology, ONCOLOGY journal, The ASCO Post, OncLive, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Apar Kishor

Contact Apar Kishor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Perceived Barriers and Facilitators to Physical Activity Engagement Among Cancer Survivors: A Qualitative Study

|
By GAURAV KUMAR, Priyanka Chaudhary, Apar Kishor Ganti, Jungyoon Kim
| preprints.org
Submitted: 09 January 2026 You are already at the latest version Background: Although physical activity (PA) offers substantial physical and psychosocial benefits, engagement remain suboptimal among cancer survivors. A theory-informed understanding of survivors’ perceived barriers, facilitators, and recommendations is needed to inform patient-centered PA survivorship interventions.
Open in Who Shared Issue with article?

Hematology and Oncology Staffing Levels for Fiscal Years 19–24 | MDedge

|
By Christina Yong, Apar Kishor Ganti, Katherine Faricy-Anderson, Richard McShinsky
| MDEdge Verified
Background Department of Veterans Affairs (VA) faces a landscape of increasingly complex practice, especially in Hematology/Oncology (H/O), and a nationwide shortage of healthcare providers, while serving more Veterans than ever before.
Open in Who Shared Issue with article?

Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer

|
By Apar Kishor Ganti, Ralph B. D’Agostino, Victoria Allan, Patricia Prince
| Taylor & Francis Online
ABSTRACT Aim Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy. Patients & methods US-based electronic medical data from Flatiron Health (01/01/2013–03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.
Open in Who Shared Issue with article?
See all 17 licensed articles (19 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified